Abstract
Background and Objectives In Parkinson’s disease (PD), Alzheimer’s disease (AD) co-pathology is common and clinically relevant. However, the longitudinal progression of AD cerebrospinal fluid (CSF) biomarkers – β-amyloid 1-42 (Aβ42), phosphorylated tau 181 (p-tau181) and total tau (t-tau) – in PD is poorly understood, and may be distinct from clinical AD. Moreover, it is unclear if CSF p-tau181 and serum neurofilament light (NfL) have added prognostic utility in PD, when combined with CSF Aβ42. First, we describe longitudinal trajectories of biofluid markers in PD. Second, we modified the AD β-amyloid/tau/neurodegeneration (ATN) framework for application in PD (ATNPD) using CSF Aβ42 (A), p-tau181 (T), and serum NfL (N), and tested ATNPD prediction of longitudinal cognitive decline in PD.
Methods Participants were selected from the Parkinson’s Progression Markers Initiative (PPMI) cohort, clinically-diagnosed with sporadic PD or as normal Controls, and followed annually for 5 years. Linear mixed effects models (LMEM) tested the interaction of diagnosis with longitudinal trajectories of analytes (log-transformed, FDR-corrected). In PD, LMEMs tested how baseline ATNPD status (AD [A+T+N±] vs. not) predicted clinical outcomes, including Montreal Cognitive Assessment (MoCA; rank-transformed, FDR-corrected).
Results Participants were 364 PD and 168 Controls, with comparable baseline mean (±SD) age (PD=62±10; Control=61±11]; Mann-Whitney-Wilcoxon: p=0.40) and gender distribution (PD=231 males [63%]; Control=107 males [64%]; chi-square: p=1.0). PD had overall lower CSF p-tau181 (β=-0.16, 95%CI=-0.23 – -0.092, p=2.2e-05) and t-tau than Controls (β=-0.13, 95%CI=-0.19 – -0.065, p=4.0e-04), but not Aβ42 (p=0.061) or NfL (p=0.32). Over time, PD had greater increases in serum NfL than Controls (β=0.035, 95%CI=0.022 – 0.048, p=9.8e-07); PD slopes did not differ from controls for CSF Aβ42 (p=0.18), p-tau181 (p=1.0) or t-tau (p=0.96). Using ATNPD, PD classified as A+T+N± (n=32; 9%) had consistently worse cognitive decline, including on global MoCA (β=-73, 95%CI=-110 – -37, p=0.00077), than all other ATNPD statuses including A+ alone (A+T-N-; n=75; 21%).
Discussion In early PD, CSF p-tau181 and t-tau were low compared to Controls and did not increase over 5 year follow-up. Even so, classification using modified ATNPD (incorporating CSF p-tau181 with CSF Aβ42 and serum NfL) may identify biologically-relevant subgroups of PD to improve prediction of cognitive decline in early PD.
Competing Interest Statement
LMS received support in an investigator-initiated grant from Roche for all immunoassay reagents and instrumentation for the analyses in CSF samples of Aβ42, t-tau and ptau181. Authors report no conflicts of interest relevant to this study.
Funding Statement
This work is supported by funding from the National Institute of Aging (P30-AG072979). KAQC is supported by the Alzheimer's Association (AARF-D-619473, AARF-D-619473-RAPID). PPMI is sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and is co-funded by MJFF, Abbvie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, Eli Lilly & Co., F. Hoffman-La Roche, Ltd., GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, Meso-Scale, Piramal, Prevail Therapeutics, Pfizer, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Berily, and Voyager Therapeutics. This work was supported by a grant from MJFF.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Parkinson's Progression Marker Initiative (PPMI) is a longitudinal, observational study, with data collection from approximately 50 international sites. Data were selected on September 7, 2021 from the PPMI database. All procedures were performed with prior approval from ethical standards committees at each participating institution and with informed consent from all study participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data contained in this study were obtained from the PPMI database and are available upon request at www.ppmi-info.org.
